ATRYS HEALTH, S.A. Inactive Instrument
Atrys Health, S.A. Stock BME
Equities
ES0105148003
Healthcare Facilities & Services
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 220M 239M 326M | Sales 2025 * | 236M 257M 350M | Capitalization | 317M 345M 470M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -2.17M -2.96M | Net income 2025 * | 4M 4.34M 5.92M | EV / Sales 2024 * | 2.23 x |
| Net Debt 2024 * | 173M 188M 256M | Net Debt 2025 * | 160M 174M 238M | EV / Sales 2025 * | 2.02 x |
| P/E ratio 2024 * |
-127
x | P/E ratio 2025 * |
76
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 07-06-12 | |
| Director of Finance/CFO | - | 15-07-31 | |
| Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 16-01-31 | |
| Director/Board Member | - | - | |
Aurora Catá Sala
BRD | Director/Board Member | 60 | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| +20.09% | 85.14B | |
| -27.30% | 72.06B | |
| +2.04% | 27.07B | |
| -9.00% | 17.43B | |
| -1.14% | 16.98B | |
| +4.56% | 16.02B | |
| +69.72% | 13.06B | |
| +6.66% | 12.9B | |
| +73.30% | 12.79B |
